Business Context and Reporting Period
This Form 8-K was filed by Biozone Pharmaceuticals, Inc. on November 12, 2013. The filing reports the entry into a Material Definitive Agreement involving the Company, its subsidiaries, and MusclePharm Corporation.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a proposed asset acquisition.
Material Changes and Transaction Details
On November 12, 2013, Biozone Pharmaceuticals, Inc. and related entities entered into an Asset Purchase Agreement with MusclePharm Corporation. Key terms include:
- Assets Acquired: MusclePharm's newly formed subsidiary will acquire substantially all operating assets of Biozone, including QuSomes, HyperSorb, and EquaSomes drug delivery technologies. Cash on hand is excluded.
- Consideration: 1,200,000 shares of MusclePharm common stock.
- Share Allocation: 600,000 shares issued to the Company upon closing; 600,000 shares placed in escrow for nine months.
- Escrow Terms: MusclePharm has the option to purchase the escrowed shares at $10.00 per share in cash during the escrow period. These shares also back-stop potential indemnification claims.
Conditions, Risks, and Management Commentary
The transaction is subject to several closing conditions, including:
- Shareholder approval by the Company.
- Receipt of a fairness opinion by MusclePharm.
- Execution of a new two-year Employment Agreement between Brian Keller (President and Chief Scientific Officer) and MusclePharm.
- Other customary closing conditions.
The filing notes that the description of the agreement is qualified by reference to the full Asset Purchase Agreement filed as Exhibit 2.1.
Investor Verification Checklist
- Verify the status of shareholder approval required for the closing.
- Confirm the receipt of the fairness opinion by MusclePharm.
- Review the full Asset Purchase Agreement (Exhibit 2.1) for specific representations, warranties, and indemnification details.
- Monitor the execution of the new employment agreement for Brian Keller.
- Clarify the current market value of MusclePharm stock to assess the total consideration value.